Refine by
Targeted Radiotherapy Articles & Analysis: Older
29 news found
RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom, today announced the purchase of two RTsafe PRIME phantoms. These are the first PRIME phantoms to be installed in ...
ByRTsafe
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
Theraised capitalwill give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, thus opening a new chapter in the fight against cancer BetaGlue Technologieshasclosed a EUR 10 million equity financing round:Fin Posillipo(Petrone Group),Kairos Partners SGR,LIFTT(Venture Capital led by Stefano Buono, founder of AAA),Neva Sgr(Intesa Sanpaolo ...
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies ...
BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
” Proton therapy, a highly advanced form of radiation therapy, targets tumors with greater precision than traditional x-ray-based radiotherapy and can reduce the amount of unnecessary radiation exposure to vulnerable healthy tissue and organs. ...
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
“We believe that, in sharing our software expertise, we can immensely improve the utility and capability of this novel therapeutic approach.” BNCT targets cancer at the cellular level through selective targeting of tumor cells with a boron containing drug, followed by activation of the drug by a neutron beam. ...
Mevion Medical Systems is pleased to announce it has signed a contract with Kansas City Urology Care (KCUC) for the purchase of a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning technology. Proton therapy is a precise form of radiation therapy that can reduce the amount of unnecessary radiation exposure to healthy tissue, which has the potential to reduce side ...
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The session, “New Era in Biologically-Targeted ...
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted ...
“TAE Life Sciences is also developing comprehensive boron target drugs and a neutron technology product portfolio to enable BNCT as a new cancer treatment modality for patients globally. ...
The requirements for medical devices that are used for BNCT treatment differ substantially from the requirements for systems used in conventional radiotherapy, as material properties become degraded by neutron irradiation. ...
It's the first device of its kind, and its ability to deliver safe and effective Surgically Targeted Radiation Therapy (STaRT) for patients is groundbreaking in the neuro-oncology community." ...
Drugs being developed to expand indications for treatment and improve efficacy of BNCT for cancer treatment Only company developing comprehensive new target drug portfolio and accelerator-based neutron system TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today ...
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell ...